ATSN-201

Biologic

AAtsena Therapeutics Inc.

ATSN-201 is one of 2 biologic programs targeting Retinoschisis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinoschisisActive, not recruiting

RetinoschisisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Retinoschisis

#DrugCompanyPhaseTrials

Diamox

Teva

Phase 2

1 2

ATSN-201

AAtsena Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Recruiting

Retinoschisis

NCT05878860

Clinical

Trials by Indication[1]

Retinoschisis1 trial

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Recruiting·AAtsena Therapeutics Inc.·Phase 1/2·NCT05878860·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATSN-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATSN-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATSN-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atsena Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: AAtsena Therapeutics Inc.

ATSN-201

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Retinoschisis1 trial

References

Drug Info

Quick Facts

Related News